New combo therapy shows promise for tough bile duct cancer

NCT ID NCT07466238

Recruiting now Disease control Sponsor: Peking University Source: ClinicalTrials.gov ↗

First seen Mar 18, 2026 · Last updated May 21, 2026 · Updated 11 times

Summary

This study tests a treatment that delivers chemotherapy directly to the liver (HAIC) combined with standard drugs for people with biliary tract cancer that cannot be removed by surgery. The goal is to shrink tumors enough so that surgery becomes possible, potentially improving survival. About 40 adults with newly diagnosed cancer will receive this approach to see if it works better than current treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Peking University Cancer Hospital
RECRUITING

Beijing, 100142, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Peking University Cancer Hospital
NOT_YET_RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

BILIARY TRACT CANCER (BTC)